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Abstract
Intestinal-type adenocarcinoma (ITAC) of ethmoid is a rare tumor associated with occupational exposure to wood
and leather dusts. Polymorphisms in xenobiotic metabolizing enzymes play an important role in gene-environment
interactions and may contribute to a high degree of variance in individual susceptibility to cancer risk. The aim of
this study was to investigate by polymerase chain reaction the role of polymorphisms at CYP1A1 and GSTM1
genes in 30 ethmoid ITAC patients and 79 healthy donors. The distribution of Thr/Asn genotype at CYP1A1 codon
461 was significantly overrepresented among the patients (23.3%; P = .0422), whereas the Ile/Val genotype at
CYP1A1 codon 462 was not significantly different between cases and controls (P = .76). The GSTM1 null geno-
type was not significantly different between cases and control (P = 1), but we observed that the combined
codon 461 Thr/Asn and GSTM1 null genotype was overrepresented in the patient group (P = .0019). The results
reveal that patients with CYP1A1 codon 461 polymorphism may be at high genetic risk of ITAC and that the risk
increases in the presence of combined polymorphism of CYP1A1 and GSTM1 null genotype. This strongly sug-
gests that CYP1A1 codon 461 and GSTM1 null genotype may be useful in selecting exposed individuals at risk
for ethmoid ITAC.
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Introduction
Intestinal-type adenocarcinoma (ITAC) of the ethmoid is a rare tumor
characterized by high local aggressiveness, predominance among males,
and association with occupational exposure in particular to wood and
leather dust [1–3]. Intestinal-type adenocarcinoma is the most com-
mon histotype in all European series of patients treated with anterior
craniofacial resection [4–6], whereas it is very rare in American series
[7–9]. A widespread use of masks and aspiration devices in American
furniture industries may probably explain this difference. The standard
treatment of this tumor remains surgery and radiotherapy [10], even if
recently complemented by chemotherapy [11].
Given the close correlation between ethmoid ITAC and exposure
to wood and leather dust, the relationship between polymorphisms of
genes involved in the metabolism of xenobiotics and cancer suscep-
tibility is of significant interest because they are thought to predis-
pose the risk of an individual if exposed to a chemical.
Most carcinogens are processed by metabolizing enzymes in two
broad steps. The phase I enzymes (CYP450 superfamily) mediate
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the metabolic “activation” of environmental carcinogens that is re-
quired for their interactions with DNA and their genotoxic effect.
The phase II enzymes (glutathione S -transferase, or GST family) are
responsible for biotransforming and detoxifying carcinogens. Com-
petition and interplay between phase I and II metabolic pathways
modulate the levels of DNA adducts, and so the genetic variability in
metabolic activities related to these enzymes may influence the risk of
cancer development.
Two polymorphisms of the CYP1A1 gene, belonging to CYP450
superfamily, have been related to cancer susceptibility: a C→ A tran-
sition leading to a substitution of threonine for asparagine at codon
461 (Thr461Asn) [12] and an A→ G transition leading to a substi-
tution of isoleucine for valine at codon 462 (Ile462Val) [13]. More-
over, GST gene polymorphisms consisting of a structural deletion
that confers a null genotype have been associated with a higher risk
of cancer [14,15].
A number of groups have investigated the possible association be-
tween the polymorphic variants of metabolizing enzymes such as
CYP1A1 and GSTM1 in oral squamous cell carcinoma (SCC), some-
times with conflicting results. One study of a Japanese patient cohort
found that patients with specific polymorphisms in these genes have
a genetically higher risk of tumor development [16], whereas no such
association was observed in a German population [17]. Considering
other tumor types and the smoking habit, it has been reported that
the CYP1A1 Ile462Val variant is associated with a three-fold in-
creased risk of lung carcinoma in Japan [18], although this was
not confirmed by a similar study in Finland [19]. It has also been
reported that CYP1A1-GSTM1 polymorphisms are associated with
a grater risk of colorectal cancer [20].
The aim of this case-control study was to investigate ethmoid
ITACs for polymorphisms of the CYP1A1 and GSTM1 metabolizing
enzymes. We found (and reported for the first time to the best of our
knowledge) that CYP1A1 codon 461 polymorphism is overrepresented
in ITAC patients in comparison with controls, and often associated
with the GSTM1 null genotype, thus suggesting that these poly-
morphisms may be associated with a high degree of susceptibility to
this type of tumor.
Materials and Methods
Study Group
The patients’ cohort consisted of a total of 30 patients with histo-
logically documented ITAC of ethmoid, surgically resected at the
Fondazione IRCSS Istituto Nazionale Tumori, Milan, between 1988
and 2007.
All patients were male and presented a disease onset mean age of
60 years (range, 41-78 years). Nineteen patients were occupationally
exposed to wood dust, and 10 to leather dust; the one remaining
showed a nonspecific exposure (Table 1).
The first 15 cases were previously investigated for alterations in the
TP53, p14ARF, p16INKα, and HRAS genes [21] and for deregulation
of the APC-βcatenin and KRAS-BRAF pathways, along with loss of
heterozygosity at 18q [22]. In this study, we applied the same case
numeration as that used in our previous studies.
The control group consisted of 79 consecutive blood donors with
no history of cancer (a patient/control ratio of approximately 1:2) who
were firstly surveyed by means of a questionnaire to determine their
suitability to be blood donor and to obtain information about de-
mographic factors. This control group including 79 men (mean age,
53 years; range, 31-70 years) was homogeneous in terms of race (whites)
and residence (Italy) without any documented exposure history.
DNA Extraction
For the first 15 patients, the analyses were made using formalin-
fixed paraffin-embedded specimens, whereas fixed and/or whole
blood samples were available for the remaining patients.
DNA was isolated from formalin-fixed paraffin-embedded tumor
sections and peripheral blood following the instructions of DNA
purification kit (Qiagen, Chatsworth, CA).
CYP1A1 Analysis
The Thr461Asn and Ile462Val polymorphisms were detected by
means of polymerase chain reaction (PCR) using primer sequences
5′-AACGGTTTCTCACCCCTGAT-3′ and 5′-GGTCATGTC-
CACCTTCACG-3′. The PCRwas carried out with 100 ng of genomic
DNA in 25 μl of a mixture containing 25 mM MgCl2, 2.5 μl of
1× PCR Buffer (Bionova, Cambridge, United Kingdom), 0.4 μM of
each primer, 0.2 mM deoxyribonucleotide triphosphates, and 2.5 U
of Taq Gold (Applied Biosystems, Foster City, CA). After initial de-
naturation at 95°C for 8 minutes, amplification was performed for
35 cycles at 95°C (30 seconds), 59°C (30 seconds), 72°C (1 minute),
followed by final elongation at 72°C (7 minutes). The PCR products
were resolved by means of agarose gel electrophoresis, and DNA frag-
ments were sequenced using an automated DNA sequencer (ABI
PRISM, 3100, Genetic Analyzer, Applied Biosystems, Foster City, CA).
Table 1. Gender, Age, Histotype, and Professional Exposure of the Patients Involved in the Study.
N Age/Gender Histotype Professional Exposure
T1 58/M PTCC II Leather dust
T2 56/M PTCC II Wood dust
T3 75/M PTCC II Wood dust
T4 67/M PTCC II Wood dust
T5 63/M AGE Leather dust
T10 50/M PTCC II Wood dust
T11 55/M AGE Leather dust
T12 51/M PTCC II Wood dust
T13 43/M PTCC II Wood dust
T14 78/M PTCC II + AGE Leather dust
T16 63/M PTCC II Wood dust
T17 49/M PTCC II Leather dust
T18 63/M PTCC II Wood dust
T19 64/M SRC Aspecific
T21 77/M PTCC II Wood dust
T22 41/M PTCC II Wood dust
T23 64/M PTCC II Wood dust
T24 63/M PTCC II Leather dust
T26 68/M AGE Wood dust
T27 67/M PTCC II Wood dust
T28 58/M PTCC II Wood dust
T29 69/M AGE Leather dust
T30 63/M PTCC II Wood dust
T31 68/M PTCC II Leather dust
T32 64/M PTCC II Wood dust
T33 50/M PTCC II Wood dust
T34 72/M AGE Leather dust
T35 60/M PTCC II Leather dust
T36 51/M PTCC II Wood dust
T37 43/M PTCC II Wood dust
AGE indicates alveolar-globet cell; M , male; PTCC, papillary-tubular cylinder cell; SRC, signet-
ring cell.
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GSTM1 Analysis
The null genotype assay was carried out by a comparative duplex
PCR. The primers used to amplify a 230-bp fragment of GSTM1
gene were 5′-GAACTCCCTGAAAAGCTAAAGC-3′ and 5′-
GTTGGGCTCAAATATACGGTGG-3′ [23].
β-Globin gene was amplified in the same reaction as an internal
positive control with primers 5′-ACACAACTGTGTTCACTAGC-
3′ and 5′-GCAAGACTTCTCCTCAGGAG-3′. Amplification was
performed for 35 cycles under the following conditions: 30-second
denaturation at 97.5°C, 1-minute primer annealing at 50°C, and
30-second primer extension at 72°C.
Statistical Analysis
The CYP1A1 and GSTM1 polymorphisms were described by re-
porting the absolute frequencies and corresponding percentages of
CYP1A1 codon 461 and 462 and GSTM1 genotypes in ITAC patients
and controls as a whole or in subgroups defined by age (≤60 years or
>60 years). CYP1A1 codon 461 was also analyzed according to the
GSTM1 genotype because it was possible to anticipate an interaction
between them.
The observed and expected genotype frequencies in the controls
were compared using the Hardy-Weinberg equilibrium theory. The
differences in the frequencies of genotypes and the individual alleles
between cases and controls, as well as between the subgroups, were
assessed using Fisher’s exact tests. Exact odds ratios (ORs) and the
corresponding 95% confidence limits (CL) were also calculated as
a measure of association, with ORs of 1 denoting the absence of as-
sociation and those more than or less than 1 indicating an overrep-
resented or underrepresented genotype, respectively, in the cases
compared with controls. The possible interaction between CYP1A1
codon 461 and GSTM1 genotypes was checked using the Breslow-
Day test. All P values reported are two-sided, and the threshold used
for statistical significance was 5%.
Results
CYP1A1 Polymorphisms: Thr461Asn and Ile462Val
Firstly, the analyses were performed on 15 formalin-fixed paraffin-
embedded ITAC samples (T1-T21) of which blood samples were not
available. Subsequently, we analyzed both fixed tumor and the cor-
responding blood samples available in four new patients (T22-T26).
The genotypes Thr/Thr and Thr/Asn at codon 461 of CYP1A1 were
found in three and one fixed ITACs, as well as in the corresponding
blood samples. Thus, we exclusively analyzed the blood samples of
11 additional new ITAC patients (T27-T37).
The distribution of CYP1A1 codon 461 and 462 polymorphisms
in ethmoid ITAC cases and controls is shown in Table 2.
The frequencies of the Thr/Thr, Thr/Asn, and Asn/Asn genotypes
at codon 461 in the control group were 92.4%, 7.6%, and 0%, re-
spectively, in agreement with the Hardy-Weinberg equilibrium (exact
P = 1.00); the corresponding frequencies in the ITAC one were of
76.7%, 23.3%, and 0%, respectively. The overall difference between
cases and controls for CYP1A1 polymorphism at codon 461 was sta-
tistically significant (P = .0422) and corresponded to a more frequent
Asn allele (from 3.8% in controls to 11.7% in the cases). The Thr/Asn
genotype was significantly overrepresented among the cases (OR =
3.70; 95% CL, 1.13, 12.1; Figure 1).
The frequencies of Ile/Ile, Ile/Val, and Val/Val genotypes at codon
462 among the controls were 92.1%, 6.6%, and 1.3%, respectively,
again in agreement with the Hardy-Weinberg equilibrium (exact P =
.13), whereas the corresponding figures among the cases were 96.7%,
3.3%, and 0%, respectively. The genotype distribution was not sig-
nificantly different between cases and controls (P = .76).
GSTM1 Null Genotype Assay
The analysis was performed in 24 ethmoid ITAC cases owing to
an unsuccessful PCR amplification of the other six specimens.
Thirteen ethmoid ITAC patients (54%) carried the GSTM1 null ge-
notype and 11 (46%) revealed the GSTM1-positive genotype (Table 2
and Figure 2). In the control group, 42 (55.3%) of 76 people showed
a GSTM1 null genotype and 34 (44.7%) carried a GSTM1-positive
genotype (Table 2).
The GSTM1 null genotype was not significantly different between
cases and control (P = 1).
CYP1A1 Codon 461 and GSTM1 Interaction
The distribution of CYP1A1 codon 461 polymorphism in the
cases and controls in relation to GSTM1 genotype is shown in the
Table 3.
Table 2. Distribution of CYP1A1 and GSTM1 Polymorphisms among ITAC Patients and Control
Subjects, OR Estimates with 95% CL, and Fisher’s Exact P Values for Testing the Difference in
Genotype Distribution between Cases and Controls.
Genotype Cases Controls OR (95% CL)* P
N % N %
Overall series: 30 cases
CYP1A1 Thr461Asn
Thr/Thr 23 76.7 73 92.4 1.00
Thr/Asn 7 23.3 6 7.6 3.70 (1.13, 12.1) 0.0422
Asn/Asn 0 – 0 – –
CYP1A1 Ile462Val
Ile/Ile 29 96.7 70 92.1 1.00
Ile/Val 1 3.3 5 6.6 0.48 (0.01, 4.62) 0.7644
Val/Val 0 — 1 1.3 —
GSTM1
Positive 11 45.8 34 44.7 1.00 1.000
Null 13 54.2 42 55.3 0.96 (0.35, 2.69)
*The reference distribution for ORs computation is that of controls.
Figure 1. CYP1A1 polymorphism analysis. The assay was carried
out by DNA amplification through PCR and automatic sequencing.
The CYP1A1 nucleotide sequence analysis shows a C → A transi-
tion at codon 461 leading to the Thr/Asn genotype in a ITAC sample.
The genotype Ile/Ile was present at codon 462.
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Among the subjects with GSTM1-positive genotype, the distribu-
tion of codon 461 polymorphism was similar between cases and con-
trols, whereas the number of people carrying both CYP1A1 codon
461 polymorphism and GSTM1 null genotype was significantly
higher among the ethmoid ITAC patients than controls (P = .0019,
OR = 25.6).
The test for interaction between CYP1A1 codon 461 and GSTM1
polymorphisms was also significant (P = .0107).
Discussion
Ethmoid ITACs are uncommon tumors associated with occupa-
tional exposure to wood and other industrial dusts. In a previous
study of TP53, p16INKa, and p14ARF deregulation in a series of
ITAC, we observed a high occurrence of gene alterations, in partic-
ular, a high rate of p16INKa and p14ARF methylation and TP53 mu-
tations consisting of a G:C→ A:T transition [21], which is a type of
mutation that is typically related to carcinogen exposure [24].
Starting from these findings suggesting a causal relationship be-
tween the presence of genotoxic agents and gene alterations, we de-
cided to compare the genotypes of the metabolizing enzymes
CYP1A1 and GSTM1 in these patients with those found in a group
of healthy donors to verify whether it is possible to identify subjects
with tumor risk.
To the best of our knowledge, this is the first time that the associa-
tion between CYP1A1 and GSTM1 polymorphisms has been evalu-
ated in ITAC.
The results showed that Thr/Asn genotype at CYP1A1 codon 461
was significantly overrepresented among these patients, suggesting
that Thr/Asn genotype could lead to greater susceptibility to ethmoid
ITAC. On the contrary, no significant difference was found in the
distribution of the CYP1A1 codon 462 and GSTM1 null genotype
between cases and controls. Little is known about the biological sig-
nificance of CYP1A1 codon 461 polymorphism, but, on the basis of
the current preclinical evidence [25–27], it is possible that the 461
variant may lead to greater catalytic activity, thus favoring an accumu-
lation of activated carcinogens, which, coupled with a less-efficient
detoxification by GSTM1, could increase the risk of ethmoid ITAC.
We therefore assessed the relative risks for the combinations of
the CYP1A1 and GSTM1 genotypes and observed that a combined
codon 461 Thr/Asn and GSTM1 null genotype segregated among
ethmoid ITAC patients with an odds ratio of 25.6. This value was
higher than that observed for the CYP1A1 Thr/Asn polymorphism
alone (OR = 3.70). Similar results have been reported by Sato et al.
[16], whose study revealed an higher occurrence of oral SCC in pa-
tients with both polymorphisms, although the CYP1A1 gene poly-
morphism was at codon 462 instead of codon 461. These findings
indicate that the loss of metabolic balance between the activation of
carcinogens by the Thr/Asn genotype of CYP1A1 and their detoxifi-
cation by GSTM1 is synergistic, perhaps involving CYP1A1 different
codons depending on the tumor type.
Polymorphisms of CYP1A1 and GSTM1 genes have also been de-
scribed in colorectal cancer [20], a tumor with histopathological re-
semblance to ITAC despite a different etiology. Interestingly, we have
previously reported genetic alterations in ethmoid ITAC patients that
are similar to those observed in colorectal cancer, including TP53,
APC, and KRAS mutations and loss of heterozygosity of chromosome
18q [21,22]. In this context, our findings of CYP1A1 and GSTM1
polymorphisms in ethmoid ITAC provide further evidence that the
morphologic similarities between ITAC and CRC mirror resemblance
at a genetic level. However, recent results showed in ITAC absence of
microsatellite instability, occurring in 10% to 15% of colorectal cancer
[28], and a pattern of gains and losses only partially similar to colorectal
cancer [29].
No information of genotype distribution is expected from age be-
cause of the small number of patients and from gender because of the
preponderance of males among subjects with ITAC of ethmoid due
to occupational exposure.
In conclusion, starting from the overrepresentation of the deregu-
lation of the two metabolizing enzymes here investigated in ethmoid
ITAC patients, we can assume that individuals with CYP1A1 codon
461 polymorphism are genetically at high risk of developing ITAC
of ethmoid and that the risk increases in the presence of combined
genotyping of CYP1A1 and GSTM1 genes. Nevertheless, to draw de-
finitive conclusions, these preliminary results need to be confirmed
in a larger number of ITAC cases and extended to a control group rep-
resented by a cohort of professionally exposed individuals who did not
develop the disease. If these future analyses will confirm the role of these
two polymorphisms in the ITAC susceptibility, CYP1A1 codon 461
and GSTM1 null genotype characterization may be useful in selecting
Figure 2. GSTM1 null genotype analysis. The assay was carried out
by a comparative duplex PCR. The GSTM gene (lower band) was
coamplified with a β-globin fragment gene (upper band). A visible
specific GSTM PCR product in lane 3 indicates the retention of
GSTM, whereas the absence of the PCR product in lanes 1 and 2
indicates the GSTM null genotype. The presence of the house-
keeping β-globin PCR product in all lanes indicates a good DNA
integrity. M indicates marker (1-kb ladder).
Table 3. Distribution of CYP1A1 Codon 461 Polymorphism among ITAC Patients and Control
Subjects, OR Estimates with 95% CL, and Fisher’s Exact P Values for Testing the Difference in
Genotype Distribution between Cases and Controls.
GSTM1 Genotype: 24 Cases Cases Controls OR (95% CL)* P†
N % N %
Positive: 11 cases
CYP1A1 Thr461Asn
Thr/Thr 10 90.9 29 85.3 1.00 1.000
Thr/Asn 1 9.1 5 14.7 0.58 (0.01, 6.24)
Null: 13 cases
CYP1A1 Thr461Asn
Thr/Thr 8 61.5 41 97.6 1.00
Thr/Asn 5 38.5 1 2.4 25.6 (2.23, >50.0) 0.0019
Figures are shown according to the GSTM1 genotype.
*The reference distribution for ORs computation is that of controls.
†P = .0107 for the interaction.
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and monitoring individuals at risk for developing ethmoid ITAC due to
occupational exposure to carcinogens. Furthermore, as different popu-
lations with other tumor types, such as HNSCC and lung carcinoma
[15–17], show variations in the distribution of CYP1A1 and GSTM1
polymorphisms, it is necessary to verify whether such epidemiological and
geographical differences can also be observed in ethmoid ITAC patients.
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